AWARD NUMBER: W81XWH-20-1-0740

TITLE: Gut Microbiome as a Predictor of Response to Chemotherapy in Metastatic Colorectal Cancer

PRINCIPAL INVESTIGATOR: Dr. Nipun Merchant

CONTRACTING ORGANIZATION: UNIVERSITY OF MIAMI, CORAL GABLES MIAMI FL 33136-1015

REPORT DATE: OCTOBER 2021

TYPE OF REPORT: ANNUAL

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

2. REPORT TYPE

1. REPORT DATE

Form Approved OMB No. 0704-0188

3. DATES COVERED

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

OCTOBER 2021		ANNUAL		15	SEPT2020 - 14SEPT2021
4. TITLE AND SUBTIT	ΓLE			5a	CONTRACT NUMBER
				W	/81XWH- 20-1-0740
				5b	. GRANT NUMBER
Gut Microbiome as a	Predictor of Response	e to Chemotherapy in N	Metastatic Colorectal Ca	ancer	
		,,, ,		5c.	PROGRAM ELEMENT NUMBER
6. AUTHOR(S)				5d	PROJECT NUMBER
				5e.	TASK NUMBER
Dr. Nipun Merchant					WORK HAIT AUMPED
				51.	WORK UNIT NUMBER
E-Mail:	GANIZATION NAME(S)	AND ADDDESS/ES)		0	PERFORMING ORGANIZATION REPORT
7. FERFORMING OR	SANIZATION NAME(S)	AND ADDRESS(ES)		_	NUMBER
UNIVERSITY OF	MIAMI, CORAL (GABLES			
MIAMI FL 3313	6-1015				
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)					SPONSOR/MONITOR'S ACRONYM(S)
•	I Research and Ma	teriel Command			
Fort Detrick, Mary	land 21702-5012			11.	SPONSOR/MONITOR'S REPORT
					NUMBER(S)
12. DISTRIBUTION / /	AVAILABILITY STATEM	MENT			
Approved for Bubl	ic Release; Distribu	ition Unlimited			
Approved for Fubi	ic Nelease, Distribu	illon Omminited			
13. SUPPLEMENTAR	Y NOTES				
10. OOI I EEMERTAR	1110120				
14. ABSTRACT: Desi	oite decades of research	ch. a combination of cv	totoxic chemotherapie	s continues to b	e the first line treatment for
					30% experiencing only
		g despite chemotherap			
		ermore, whether there			predict response to microbiome in health as well
					t gut microbiota supports
					e bacterial communities in
		selective gut microbion			
					nicrobiome can modulate interaction of gut microbiome
					ance, it has been observed
		efficacy of Oxaliplatin is			
		ature as well as our pre			novel hypothesis: Gut of care chemotherapy.
		d emerge as novel there			
chemotherapy immu		ŭ		•	th an interventional animal
study component.					
15. SUBJECT TERMS NONE LISTED	5				
	PIEICATION OF		47 LIBRITATION	40 1111112	400 NAME OF RESPONSIBLE BERGEN
16. SECURITY CLASS	DIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE	-		19b. TELEPHONE NUMBER (include area
a. ILLI OILI	D. ADDITACT	G. ITHIS I AGE	Unclassified	_	code)
Unclassified	Unclassified	Unclassified	Unclassified	5	
2			I	I	Standard Form 298 (Rev. 8-98)

1. INTRODUCTION:

Despite decades of research, a combination of cytotoxic chemotherapies continues to be the first line treatment for metastatic colon and rectal cancer (CRC). Patients typically respond variably to chemotherapy with ~20-30% experiencing only disease stability and up to 30% progressing despite chemotherapy. Currently there are no known and validated predictors of response to cytotoxic chemotherapy. Furthermore, whether there are any patient related factors, which predict response to chemotherapy, is not known.

Recent years have seen an increase in our understanding of the role of gut microbiome in health as well as in the pathogenesis of various diseases. Recent research from our group and others have shown that gut microbiota supports growth of colon, pancreatic and many other cancers. Our preliminary studies also suggest that not all the bacterial communities in gut microbiome promote tumor growth as selective gut microbiome modulation by individual antibiotics like vancomycin or metronidazole has similar effects Interestingly, our preliminary data in animal models suggest that gut microbiome can modulate response of cancer to various therapeutic strategies including chemotherapy and immunotherapy. This interaction of gut microbiome and chemotherapy in the treatment of colon cancer has been observed by other groups as well. For instance, it has been observed that in the absence of gut microbiome the efficacy of Oxaliplatin is reduced and this may be due partially to an impaired ROS production by myeloid cells. Based on literature as well as our preliminary studies we have proposed a novel hypothesis: *Gut microbiome composition can predict response of patients with metastatic colorectal cancer to standard of care chemotherapy. Selective gut microbiome modulation could emerge as novel therapeutic strategy to improve response to standard of care chemotherapy and/or immunotherapy.* This hypothesis will be tested through an observational clinical study with an interventional animal study component.

2. KEYWORDS:

Colorectal Cancer, Metastasis, Pancreatic Cancer, Gut, Microbiome, Chemotherapy, Antibiotics, Immunotherapy.

3. ACCOMPLISHMENTS:

• Major goals of the project:

Specific aim 1- Does Gut Microbiome composition predicts response to chemotherapy?

Major Task: Recruitment of 1st 30 Subjects, baseline imaging, gut microbiome collection, initiation of chemotherapy in 1st 30 subjects, completion of 4 months of chemotherapy on recruited subjects, collection of post chemotherapy samples of gut microbiome. Contributor: Vikas Dudeja (PI) & Nipun Merchant (Co-PI).

Specific aim 2- Does modulation of gut microbiome modify response to chemotherapy?

Major task: Generation of human gut microbiome avatar mice by transplanting stool from 10 responders, 10 patients with stable disease and 10 patients with progressive disease into germ free mice. Implantation of colon cancer cell lines subcutaneously in human gut microbiome avatar mice. Contributor: Vikas Dudeja (PI) & Ashok Saluja (Co-PI).

• Accomplishment under these goals:

For Aim 1, we have acquired IRB approval at University of Miami. However, based on recommendations by the HRPO, we are awaiting conversion of our IRB to a single site IRB to be initiated by UAB. We have submitted our documents to UAB for final approval. Personnel for recruitment of specimens is right now in place.

For Aim 2, we have obtained IACUC approval as well as ACUR approval. We are waiting on IRB and HRPO approval so that we can collect gut microbiome specimens, which will be used for generation of Human Gut Microbiome AVATAR mice.

- Opportunities for training and professional development: Nothing to report
- Dissemination of results to community of interest: Nothing to report
- Plan to do during next reporting period to accomplish the goals:

As soon as we receive this single site IRB approval, we will recruit patients with metastatic colorectal cancer and collect stool for gut microbiome analysis. Subsequently, these patients will receive will recruit patients with metastatic colorectal cancer and collected stool for gut microbiome. Subsequently, these patients received chemotherapy FOLFOX and Avastin for 4 months. After 4 months, treatment response was evaluated by cross sectional imaging and stool will again be collected for gut microbiome analysis and used for the second aim of the grant (PI: Dudeja and Saluja).

4. IMPACT:

- Impact on the development of the principal discipline(s) of the project: Nothing to report
- Impact on other disciplines: Nothing to report
- Impact on technology transfer: Nothing to report
- Impact on society beyond science and technology: Nothing to report
- 5. CHANGES/PROBLEMS: Nothing to report

6. PRODUCTS:

• Publications, conference papers, and presentations:

Journal Publications: Nothing to report

Book or other non-periodical, one-time publications: Nothing to report **Other publications, conference papers, and presentations:** Nothing to report

- Website(s) or other internet sites(s): Nothing to report
- Technologies and techniques: Nothing to report
- Inventions, patent applications, and/or licenses: Nothing to report
- Other products: Nothing to report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS:

• Individuals worked on the project:

Name:	Nipun Merchant, MD
Project Role:	Co-PI

Researcher Identifier:	
Nearest person month	6
worked:	
Contribution to Project:	Aim 1: Does Gut Microbiome Composition Predict Response to Chemotherapy?
Funding Support:	Not applicable

- Change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period: Nothing to report
- Other organizations involved as partners: Nothing to report

8. SPECIAL REPORTING REQUIREMENTS:

Collaborative Awards: Nothing to report

Quad Charts: Nothing to report

9. APPENDICES: Nothing to report